NEW BRUNSWICK, N.J.—Johnson & Johnson (NYSE: JNJ) announced on Tuesday the results for third-quarter 2023. The company reported worldwide sales growth of 6.8 percent to $21.4 billion with operational growth of 6.4 percent and adjusted operational growth of 4.9 percent. It also increased 2023 full-year guidance midpoints for sales and adjusted EPS. The reported results mark the company’s first quarterly results since it completed the separation from its consumer health spinoff Kenvue in August 2023.

“Johnson & Johnson delivered strong results and significant pipeline advances in the third quarter, providing a solid foundation for future sustained growth,” said Joaquin Duato, chairman of the board and chief executive officer. “With a sharpened focus on Innovative Medicine and MedTech solutions, Johnson & Johnson is innovating across the spectrum of healthcare and is poised to deliver the medical breakthroughs of tomorrow.”

MedTech worldwide adjusted operational sales grew 6.0 percent, driven primarily by electrophysiology products in Interventional Solutions, wound closure products in General Surgery, contact lenses in Vision, and biosurgery in Advanced Surgery. MedTech worldwide operational sales grew 10.4 percent, with the acquisition of Abiomed contributing 4.6 percent. Worldwide sales of contact lenses increased 2.2 percent, although sales in the U.S. were off 1.2 percent. Growth was driven by continued strong performance of the Acuvue Oasys 1-Day family and commercial execution.

Innovative Medicine worldwide adjusted operational sales grew 4.4 percent. Excluding the COVID-19 vaccine, operational sales grew 8.2 percent. Growth was driven by Darzalex (daratumumab), Erleada (apalutamide), Other Oncology, and Carvykti (ciltacabtagene autoleucel) in Oncology, Stelara (ustekinumab), Tremfya (guselkumab), and Simponi/Simponi Aria (golimumab) in Immunology, Spravato (esketamine) in Neuroscience, and Uptravi (selexipag) in Pulmonary Hypertension.

Johnson & Johnson reported Q3 net income of $4.31 billion. That was flat compared with net income of $4.31 billion for the same period a year ago.

The company expects 2023 sales of $83.6 billion to $84 billion, compared to a previous guidance of $83.2 billion to $84 billion in August.

“We are confident that Johnson & Johnson’s strong performance through the first nine months of this year will continue, and as a result, we have increased our guidance for 2023,” said Joe Wolk, executive vice president and chief financial officer, Johnson & Johnson. “The strength of our business, the promise of our Innovative Medicine and MedTech pipelines, and our 130,000 colleagues around the world position us well for long-term growth and significant value creation for shareholders.”